Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 17;9(4):226. doi: 10.3390/diagnostics9040226

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Blood serum migration inhibitory factor (MIF) levels throughout PPS treatment. Three adult males with attenuated MPS II were administered weekly PPS injections for 12 weeks at a dosage of 0.5 mg/kg for the first injection and 1.0 mg/kg for all subsequent injections. Patients 1, 2, and 3, are represented by (a), (b), and (c), respectively. Blood serum samples were measured for MIF levels using a human antibody enzyme-linked immunosorbent assay (ELISA) (R and D Systems) at the start of the clinical trial, before weekly PPS injections, and were then taken every 4 weeks for 16 weeks in Patients 2 and 3 before the injection. For Patient 1, measurements were taken at weeks 4, 10, 14, and 17, as a seizure occurred between injections 7 and 8 and treatment was halted for two weeks. Bars represent standard error of the mean (n = 3). The red, double-headed arrows indicate the start and end of the PPS injection period.

Blood serum migration inhibitory factor (MIF) levels throughout PPS treatment. Three adult males with attenuated MPS II were administered weekly PPS injections for 12 weeks at a dosage of 0.5 mg/kg for the first injection and 1.0 mg/kg for all subsequent injections. Patients 1, 2, and 3, are represented by (a), (b), and (c), respectively. Blood serum samples were measured for MIF levels using a human antibody enzyme-linked immunosorbent assay (ELISA) (R and D Systems) at the start of the clinical trial, before weekly PPS injections, and were then taken every 4 weeks for 16 weeks in Patients 2 and 3 before the injection. For Patient 1, measurements were taken at weeks 4, 10, 14, and 17, as a seizure occurred between injections 7 and 8 and treatment was halted for two weeks. Bars represent standard error of the mean (n = 3). The red, double-headed arrows indicate the start and end of the PPS injection period.